Taysha Gene Therapies (NASDAQ:TSHA – Get Free Report) is set to post its quarterly earnings results after the market closes on Tuesday, November 14th. Analysts expect Taysha Gene Therapies to post earnings of ($0.13) per share for the quarter. Individual interested in registering for the company’s earnings conference call can do so using this link.
Taysha Gene Therapies (NASDAQ:TSHA – Get Free Report) last released its quarterly earnings results on Monday, August 14th. The company reported ($0.38) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.31) by ($0.07). The company had revenue of $2.40 million for the quarter, compared to analysts’ expectations of $2.00 million. On average, analysts expect Taysha Gene Therapies to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Taysha Gene Therapies Price Performance
Taysha Gene Therapies stock opened at $1.51 on Friday. Taysha Gene Therapies has a 12-month low of $0.50 and a 12-month high of $3.89. The company has a market capitalization of $281.37 million, a price-to-earnings ratio of -0.66 and a beta of 0.13. The firm’s fifty day moving average price is $2.70 and its 200 day moving average price is $1.59.
Wall Street Analysts Forecast Growth
Insider Activity at Taysha Gene Therapies
In other news, CFO Kamran Alam sold 33,000 shares of the company’s stock in a transaction that occurred on Thursday, August 24th. The stock was sold at an average price of $2.33, for a total transaction of $76,890.00. Following the completion of the transaction, the chief financial officer now directly owns 258,042 shares of the company’s stock, valued at $601,237.86. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, major shareholder Paul B. Manning purchased 16,466,667 shares of the stock in a transaction dated Wednesday, August 16th. The stock was acquired at an average price of $0.90 per share, for a total transaction of $14,820,000.30. Following the completion of the transaction, the insider now owns 16,466,667 shares of the company’s stock, valued at $14,820,000.30. The purchase was disclosed in a filing with the SEC, which is available at the SEC website. Also, CFO Kamran Alam sold 33,000 shares of the company’s stock in a transaction dated Thursday, August 24th. The stock was sold at an average price of $2.33, for a total transaction of $76,890.00. Following the completion of the transaction, the chief financial officer now owns 258,042 shares of the company’s stock, valued at approximately $601,237.86. The disclosure for this sale can be found here. Insiders acquired a total of 17,300,000 shares of company stock valued at $15,570,000 in the last quarter. Insiders own 2.25% of the company’s stock.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently bought and sold shares of the company. Maven Securities LTD bought a new position in Taysha Gene Therapies in the 4th quarter worth approximately $34,000. AQR Capital Management LLC bought a new position in shares of Taysha Gene Therapies in the second quarter worth $38,000. XTX Topco Ltd bought a new position in shares of Taysha Gene Therapies in the first quarter worth $68,000. Bank of America Corp DE grew its position in Taysha Gene Therapies by 172.0% in the 1st quarter. Bank of America Corp DE now owns 137,001 shares of the company’s stock valued at $109,000 after buying an additional 86,625 shares in the last quarter. Finally, Occudo Quantitative Strategies LP grew its position in Taysha Gene Therapies by 17.9% in the 2nd quarter. Occudo Quantitative Strategies LP now owns 31,030 shares of the company’s stock valued at $115,000 after buying an additional 4,702 shares in the last quarter. Institutional investors own 25.91% of the company’s stock.
About Taysha Gene Therapies
Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis.
- Five stocks we like better than Taysha Gene Therapies
- What is the Hang Seng index?
- MarketBeat Week in Review – 11/6 – 11/10
- What Are Dividend Contenders? Investing in Dividend Contenders
- Data giants MongoDB and Snowflake just got upgraded
- Best Aerospace Stocks Investing
- Plug Power at tipping point; it’s make or break time for hydrogen
Receive News & Ratings for Taysha Gene Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Taysha Gene Therapies and related companies with MarketBeat.com's FREE daily email newsletter.